Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review

被引：73
作者：
Kulkarni, Abhijeet D. [1 ]
Vanjari, Yogesh H. [1 ]
Sancheti, Karan H. [1 ]
Belgamwar, Veena S. [2 ]
Surana, Sanjay J. [3 ]
Pardeshi, Chandrakantsing V. [1 ]
机构：
[1] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut, Ind Pharm Lab, Shirpur 425405, Maharashtra, India
[2] RTM Nagpur Univ, Dept Pharmaceut Sci, Nagpur, Maharashtra, India
[3] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmacognosy, Shirpur, Maharashtra, India
来源：
JOURNAL OF DRUG TARGETING | 2015年 / 23卷 / 09期
关键词：
Blood-brain barrier; brain-blood ratio; nanomedicines; nanotechnology; nasal drug delivery; neurodegenerative disorders; nose to brain; Parkinson's disease; CENTRAL-NERVOUS-SYSTEM; INTRANASAL CARRIERS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; P-GLYCOPROTEIN; BASAL GANGLIA; LEWY BODIES; IN-VITRO; NANOPARTICLES; THERAPY;
D O I：
10.3109/1061186X.2015.1020809
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Nose to brain delivery of neurotherapeutics have been tried by several researchers to explore the virtues of this route viz. circumvention of BBB, avoidance of hepatic metabolism, practicality, safety, ease of administration and non-invasiveness. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson's disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This review presents a concise incursion into the nanomedicines suitable for PD therapy delivered via naso-brain transport. Clinical signs of PD, its pathophysiology, specific genetic determinants, diagnosis and therapy involved have been hashed out. Properties of brain-targeting NPs, transport efficacy and various nanocarriers developed so far also been furnished. In our opinion, nanotechnology-enabled naso-brain drug delivery is an excellent means of delivering neurotherapeutics and is a promising avenue for researchers to develop new formulations for the effective management of PD.
引用
收藏
页码：775 / 788
页数：14
相关论文
共 97 条
[91]   Cell replacement therapy for Parkinson's disease [J].
Wijeyekoon, Ruwani ;
Barker, Roger A. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2009, 1792 (07) :688-702
[92]  
Wilson B., 2009, NANOMEDICINE, V6, P144
[93]   Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease [J].
Wilson, Barnabas ;
Samanta, Malay Kumar ;
Santhi, Kumaraswamy ;
Kumar, Kokilampal Perumal Sampath ;
Paramakrishnan, Nallupillai ;
Suresh, Bhojraj .
BRAIN RESEARCH, 2008, 1200 :159-168
[94]   Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease [J].
Zaja-Milatovic, S ;
Milatovic, D ;
Schantz, AM ;
Zhang, J ;
Montine, KS ;
Samii, A ;
Deutch, AY ;
Montine, TJ .
NEUROLOGY, 2005, 64 (03) :545-547
[95]   Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform [J].
Zhang, Liangfang ;
Chan, Juliana M. ;
Gu, Frank X. ;
Rhee, June-Wha ;
Wang, Andrew Z. ;
Radovic-Moreno, Aleksandar F. ;
Alexis, Frank ;
Langer, Robert ;
Farokhzad, Omid C. .
ACS NANO, 2008, 2 (08) :1696-1702
[96]   Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats [J].
Zhao, Ying-Zheng ;
Li, Xing ;
Lu, Cui-Tao ;
Lin, Min ;
Chen, Li-Juan ;
Xiang, Qi ;
Zhang, Ming ;
Jin, Rong-Rong ;
Jiang, Xi ;
Shen, Xiao-Tong ;
Li, Xiao-Kun ;
Cai, Jun .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2014, 10 (04) :755-764
[97]   Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology [J].
Zimprich, A ;
Biskup, S ;
Leitner, P ;
Lichtner, P ;
Farrer, M ;
Lincoln, S ;
Kachergus, J ;
Hulihan, M ;
Uitti, RJ ;
Calne, DB ;
Stoessl, AJ ;
Pfeiffer, RF ;
Patenge, N ;
Carbajal, IC ;
Vieregge, P ;
Asmus, F ;
Müller-Myhsok, B ;
Dickson, DW ;
Meitinger, T ;
Strom, TM ;
Wszolek, ZK ;
Gasser, T .
NEURON, 2004, 44 (04) :601-607
12345678910